0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......

Journal Articles

in Drug Prescribing Behavior
 81-100 of 130 Articles
Invited Commentary | 
Daniel S. Budnitz, MD, MPH
Arch Intern Med. 2009;169(14):1332-1334. doi:10.1001/archinternmed.2009.180.

Original Investigation |  FREE
Michael A. Steinman, MD; Gary E. Rosenthal, MD; C. Seth Landefeld, MD; et al.
Arch Intern Med. 2009;169(14):1326-1332. doi:10.1001/archinternmed.2009.206.

Research Letters |  FREE
Andrew R. Miesner, PharmD; Daniel P. Allen, MD; Carrie F. Koenigsfeld, PharmD; et al.
Arch Intern Med. 2009;169(13):1241-1247. doi:10.1001/archinternmed.2009.171.

Editor's Correspondence | 
Arch Intern Med. 2009;169(8):810. doi:10.1001/archinternmed.2009.80.

Editor's Correspondence | 
Madhavi Bollu, MD; Andres C. Marte-Grau, MD; Ravi K. Bobba, MD
Arch Intern Med. 2009;169(8):809-813. doi:10.1001/archinternmed.2009.80.

Editor's Correspondence | 
Peter A. G. M. De Smet, PharmD, PhD
Arch Intern Med. 2009;169(8):809-813. doi:10.1001/archinternmed.2009.81.

Editor's Correspondence | 
Patricia M. L. A. van den Bemt, PhD; Anne J. Leendertse, PharmD; Lennart J. Stoker, PharmD; et al.
Arch Intern Med. 2009;169(8):809-813. doi:10.1001/archinternmed.2009.82.

Original Investigation |  FREE
Michael A. Fischer, MD, MS; Christine Vogeli, PhD; Margaret Stedman, MPH; et al.
Arch Intern Med. 2008;168(22):2433-2439. doi:10.1001/archinte.168.22.2433.

Original Investigation |  FREE
Adam L. Hersh, MD, PhD; Henry F. Chambers, MD; Judith H. Maselli, MSPH; et al.
Arch Intern Med. 2008;168(14):1585-1591. doi:10.1001/archinte.168.14.1585.

Original Investigation |  FREE
Peter T. Donnan, PhD; David W. T. Dorward, MD; Bill Mutch, MD; et al.
Arch Intern Med. 2008;168(13):1416-1422. doi:10.1001/archinte.168.13.1416.

Editor's Correspondence | 
Andrea Gruneir, PhD; Kate L. Lapane, PhD
Arch Intern Med. 2008;168(2):238-239. doi:10.1001/archinternmed.2007.43.

Editor's Correspondence | 
Geoffrey M. Anderson, MD, PhD; Paula A. Rochon, MD, MPH
Arch Intern Med. 2008;168(2):239. doi:10.1001/archinternmed.2007.48.

Editorial | 
Joseph V. Agostini, MD
Arch Intern Med. 2007;167(8):753-754. doi:10.1001/archinte.167.8.753.

Original Investigation |  FREE
Paula A. Rochon, MD, MPH; Therese A. Stukel, PhD; Susan E. Bronskill, PhD; et al.
Arch Intern Med. 2007;167(7):676-683. doi:10.1001/archinte.167.7.676.

Original Investigation |  FREE
Hoangmai H. Pham, MD, MPH; G. Caleb Alexander, MD, MS; Ann S. O’Malley, MD, MPH
Arch Intern Med. 2007;167(7):663-668. doi:10.1001/archinte.167.7.663.

Editor's Correspondence | 
Jennifer L. Bright, MPA
Arch Intern Med. 2006;166(22):2554-2555. doi:10.1001/archinte.166.22.2554-b.

Editor's Correspondence | 
Randall S. Stafford, MD, PhD; David C. Radley, MPH; Stan N. Finkelstein, MD
Arch Intern Med. 2006;166(22):2554-2555. doi:10.1001/archinte.166.22.2555.

Editor's Correspondence | 
David C. Currow, MPH, FRACP; Amy P. Abernethy, MD
Arch Intern Med. 2006;166(21):2404. doi:10.1001/archinte.166.21.2404-a.

Original Investigation |  FREE
Derjung M. Tarn, MD, PhD; John Heritage, PhD; Debora A. Paterniti, PhD; et al.
Arch Intern Med. 2006;166(17):1855-1862. doi:10.1001/archinte.166.17.1855.

Editor's Correspondence | 
Robert C. Sherrick, MD
Arch Intern Med. 2006;166(13):1418. doi:10.1001/archinte.166.13.1418-a.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Subscribe to the journal
From The JAMA Network
JAMA
Medical News & Perspectives  | 
CDC: Major Disparities in Opioid Prescribing Among States:  Some States Crack Down on Excess Prescribing
Bridget M. Kuehn, MSJ
JAMA Neurology
Editorial  | 
Does Natalizumab Therapy Benefit Patients With Multiple Sclerosis?
Olaf Stüve, MD, PhD; Gary R. Cutter, PhD
JAMA Neurology
Original Investigation  | 
Treatment of Relapsing-Remitting Multiple Sclerosis After 24 Doses of Natalizumab:  Evidence From an Italian Spontaneous, Prospective, and Observational Study (the TY-STOP Study)
Marinella Clerico, MD; Irene Schiavetti, BS; Stefania F. De Mercanti, MD; et al.
JAMA
Special Communication  | 
Antiretroviral Treatment of Adult HIV Infection:  2014 Recommendations of the International Antiviral Society–USA Panel
Huldrych F. Günthard, MD; Judith A. Aberg, MD; Joseph J. Eron, MD; et al.